{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:04:13Z","timestamp":1784869453832,"version":"3.55.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Esophageal cancer often appears as postoperative metastasis or recurrence after radical surgery. Although we had previously reported that serum programmed cell death ligand 1 (PD-L1) level correlated with the prognosis of esophageal cancer, further novel biomarkers are required for more precise prediction of the prognosis. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) is associated with the cholesterol metabolism. But there was no report of relationship between serum PCSK9 antibody and cancer. Therefore, we investigated whether anti-PCSK9 antibodies could be a novel biomarker for solid cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serum levels of anti-PCSK9 antibodies and antigens in patients with solid cancer were analyzed using amplified luminescence proximity homogeneous assay-linked immunosorbent assay (AlphaLISA). The reactivity of serum antibodies against recombinant PCSK9 protein was investigated by Western blotting, and the expression of PCSK9 antigens in esophageal cancer tissues was examined by immunohistochemical staining.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>AlphaLISA showed that serum anti-PCSK9 antibody (s-PCSK9-Ab) levels were significantly higher in patients with esophageal cancer, gastric cancer, colorectal cancer, lung cancer, and breast cancer than in healthy donors, and patients with esophageal cancer had the highest levels. The presence of serum antibody in patients was confirmed by Western blotting. There was no apparent correlation between s-PCSK9-Ab and PCSK9 antigen levels. Immunohistochemical staining demonstrated the expression of PCSK9 antigen in both the cytoplasm and nuclear compartments of esophageal squamous cell carcinoma tissue but not in normal tissue. Compared with patients with low s-PCSK9-Ab levels, those with high s-PCSK9-Ab levels had a favorable postoperative prognosis after radical surgery for esophageal cancer. In the multivariate analysis, tumor depth and s-PCSK9-Ab level were identified as independent prognostic factors. In the univariate analysis of clinicopathological features, high PCSK9 antibody levels were not associated with sex, age, location, tumor depth, lymph node status, squamous cell carcinoma antigen, or p53-Ab, whereas they correlated significantly with PD-L1 levels, which were associated with unfavorable prognosis. Correlation between s-PCSK9-Ab and PD-L1 levels was also confirmed in the logistic regression analysis; therefore, low s-PCSK9-Ab levels could discriminate another poor prognosis group other than high-PD-L1 group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with solid cancer had higher s-PCSK9-Ab levels than healthy donors. High s-PCSK9-Ab levels indicated better prognosis for overall survival after surgery in patients with esophageal cancer.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.708039","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T11:32:09Z","timestamp":1629804729000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Masaaki","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Hiwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Nanami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sumazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Shiratori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Funahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Iwadate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byambasteren","family":"Jambaljav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ags3.12179","article-title":"P53 Molecular Approach to Diagnosis and Treatment of Esophageal Squamous Cell Carcinoma","volume":"2","author":"Shimada","year":"2018","journal-title":"Ann Gastroenterol Surg"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-018-0641-9","article-title":"Esophageal Cancer Practice Guidelines 2017 Edited by the Japan Esophageal Society: Part\u00a01","volume":"16","author":"Kitagawa","year":"2019","journal-title":"Esophagus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0545","article-title":"Immuno-Oncology for Esophageal Cancer","volume":"16","author":"Yamamoto","year":"2020","journal-title":"Future Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2789","article-title":"High Serum PD-L1 Level Is a Poor Prognostic Biomarker in Surgically Treated Esophageal Cancer","volume":"9","author":"Ito","year":"2020","journal-title":"Cancer Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 Cause Autosomal Dominant Hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"50630\u22128","DOI":"10.1074\/jbc.M410077200","article-title":"Post\u2212Transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin\/Kexin Type 9a in Mouse Liver","volume":"279","author":"Park","year":"2004","journal-title":"J Biol Chem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"48865\u221275","DOI":"10.1074\/jbc.M409699200","article-title":"NARC\u22121\/PCSK9 and its Natural Mutants: Zymogen Cleavage and Effects on the Low Density Lipoprotein (LDL) Receptor and LDL Cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J Biol Chem"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1595\u22129","DOI":"10.1194\/jlr.cx00001-jlr200","article-title":"PCSK9 Function and Physiology","volume":"49","author":"Peterson","year":"2008","journal-title":"J Lipid Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2009.11.008","article-title":"Loss-Of-Function Mutation R46L in the PCSK9 Gene has Little Impact on the Levels of Total Serum Cholesterol in Familial Hypercholesterolemia Heterozygotes","volume":"411","author":"Str\u00f8m","year":"2010","journal-title":"Clin Chim Acta"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3699","article-title":"The Biology and Therapeutic Targeting of the Proprotein Convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. ODYSSEY LONG TERM Investigators","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes After Acute Coronary Syndrome. ODYSSEY OUTCOMES Committees and Investigators","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients With Cardiovascular Disease. FOURIER Steering Committee and Investigators","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2613","article-title":"The Role of Cholesterol in Cancer","volume":"76","author":"Kuzu","year":"2016","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e54242","DOI":"10.1371\/journal.pone.0054242","article-title":"Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)","volume":"8","author":"Strohmaier","year":"2013","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn736","article-title":"Time-Dependent Association of Total Serum Cholesterol and Cancer Incidence in a Cohort of 172,210 Men and Women: A Prospective 19-Year Follow-Up Study","volume":"20","author":"Strasak","year":"2009","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.03.020","article-title":"Tumor-Induced Hyperlipidemia Contributes to Tumor Growth","volume":"15","author":"Huang","year":"2016","journal-title":"Cell Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, Obesity, and Mortality From Cancer in a Prospectively Studied Cohort of U.S. Adults","volume":"348","author":"Calle","year":"2003","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"111758","DOI":"10.1016\/j.biopha.2021.111758","article-title":"PCSK9 and Cancer: Rethinking the Link","volume":"140","author":"Mahboobnia","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2021.04.016","article-title":"Proprotein Convertase Subtilisin Kexin\/Type 9: A View Beyond the Canonical Cholesterol-Lowering Impact","volume":"191","author":"Macchi","year":"2021","journal-title":"Am J Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 Potentiates Immune Checkpoint Therapy for Cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22354","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9): Hepatocyte-Specific Low-Density Lipoprotein Receptor Degradation and Critical Role in Mouse Liver Regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22130","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Affects Gene Expression Pathways Beyond Cholesterol Metabolism in Liver Cells","volume":"224","author":"Lan","year":"2010","journal-title":"J Cell Physiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.21519","article-title":"Genome-Wide Expression Analysis of Cells Expressing Gain of Function Mutant D374Y-PCSK9","volume":"217","author":"Ranheim","year":"2008","journal-title":"J Cell Physiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and Inflammation: A Review of Experimental and Clinical Evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharm"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25767","article-title":"PCSK9 at the Crossroad of Cholesterol Metabolism and Immune Function During Infections","volume":"232","author":"Paciullo","year":"2017","journal-title":"J Cell Physiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/biof.1619","article-title":"Beyond Cholesterol Metabolism: The Pleiotropic Effects of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9)","volume":"46","author":"Cesaro","year":"2020","journal-title":"Genetics Mutations Expression Perspective Long Term Inhibition Biofactors"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-016-0551-7","article-title":"Japanese Classification of Esophageal Cancer, 11th Edition: Part I","volume":"14","year":"2017","journal-title":"Esophagus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23789","article-title":"Association of Serum Levels of Antibodies Against MMP1, CBX1, and CBX5 With Transient Ischemic Attack and Cerebral Infarction","volume":"9","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2020.4690","article-title":"Association Between Serum Anti-ASXL2 Antibody Levels and Acute Ischemic Stroke, Acute Myocardial Infarction, Diabetes Mellitus, Chronic Kidney Disease and Digestive Organ Cancer, and Their Possible Association With Atherosclerosis and Hypertension","volume":"46","author":"Li","year":"2020","journal-title":"Int J Mol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14652","article-title":"Serum Anti-LRPAP1 Is a Common Biomarker for Digestive Organ Cancers and Atherosclerotic Diseases","volume":"111","author":"Sumazaki","year":"2020","journal-title":"Cancer Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11092","article-title":"Japan P53 Antibody Research Group. Titration of Serum P53 Antibodies in 1,085 Patients With Various Types of Malignant Tumors: A Multiinstitutional Analysis by the Japan P53 Antibody Research Group","volume":"97","author":"Shimada","year":"2003","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2003.139","article-title":"Prediction of Survival With Squamous Cell Carcinoma Antigen in Patients With Resectable Esophageal Squamous Cell Carcinoma","volume":"133","author":"Shimada","year":"2003","journal-title":"Surgery"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-9-232","article-title":"Identification of Makorin 1 as a Novel SEREX Antigen of Esophageal Squamous Cell Carcinoma","volume":"9","author":"Shimada","year":"2009","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1477-5956-9-31","article-title":"Identification of a Novel SEREX Antigen Family, ECSA, in Esophageal Squamous Cell Carcinoma","volume":"9","author":"Kagaya","year":"2011","journal-title":"Proteome Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12967-015-0393-4","article-title":"Identification of Stroke-Associated-Antigens via Screening of Recombinant Proteins From the Human Expression cDNA Library (SEREX)","volume":"13","author":"Machida","year":"2015","journal-title":"J Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23653","article-title":"Elevation of Autoantibody Level Against PDCD11 in Patients With Transient Ischemic Attack","volume":"9","author":"Yoshida","year":"2018","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20517","article-title":"Serological Identification of TROP2 by Recombinant cDNA Expression Cloning Using Sera of Patients With Esophageal Squamous Cell Carcinoma","volume":"112","author":"Nakashima","year":"2004","journal-title":"Int J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the Freely Available Easy-to-Use Software \u2018EZR\u2019 for Medical Statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02367-z","article-title":"Serum PCSK9 Levels at the Second Nivolumab Cycle Predict Overall Survival in Elderly Patients With NSCLC: A Pilot Study","volume":"68","author":"Bonaventura","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2019.84734","article-title":"Effects of Immunization Against PCSK9 in an Experimental Model of Breast Cancer","volume":"15","author":"Momtazi-Borojeni","year":"2019","journal-title":"Arch Med Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2019.84732","article-title":"Potential Anti-Tumor Effect of a Nanoliposomal Antipcsk9 Vaccine in Mice Bearing Colorectal Cancer","volume":"15","author":"Momtazi-Borojeni","year":"2019","journal-title":"Arch Med Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40170-018-0187-2","article-title":"Hepatocellular Carcinoma-Associated Hypercholesterolemia: Involvement of Proprotein-Convertase-Subtilisin-Kexin Type-9 (PCSK9)","volume":"6","author":"Athavale","year":"2018","journal-title":"Cancer Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1188\/19.ONF.459-472","article-title":"Hyperglycemia and Cancer: A State-Of-the-Science Review","volume":"46","author":"Hammer","year":"2019","journal-title":"Oncol Nurs Forum"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9683","article-title":"Low-Density Lipoprotein Promotes Lymphatic Metastasis of Esophageal Squamous Cell Carcinoma and Is an Adverse Prognostic Factor","volume":"17","author":"Deng","year":"2019","journal-title":"Oncol Lett"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2003.11.010","article-title":"Hyperlipidemia Is a Risk Factor for Lymphatic Metastasis in Superficial Esophageal Carcinoma","volume":"208","author":"Sako","year":"2004","journal-title":"Cancer Lett"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0683","article-title":"The Low-Density Lipoprotein Receptor-Related Protein Regulates Cancer Cell Survival and Metastasis Development","volume":"67","author":"Montel","year":"2007","journal-title":"Cancer Res"},{"key":"B48","article-title":"Correlations of Recurrence After Radical Surgery for Esophageal Cancer With Glucose-Lipid Metabolism, Insulin Resistance, Inflammation, Stress and Serum P53 Expression","volume":"24","author":"Zheng","year":"2019","journal-title":"J BUON"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.708039\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T11:32:11Z","timestamp":1629804731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.708039\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":48,"alternative-id":["10.3389\/fonc.2021.708039"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.708039","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"article-number":"708039"}}